Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Phase 2 Completed 24 enrolled Sumitomo Pharma America, Inc.

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start: 2005-04
Primary completion: 2005-10
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Arformoterol	Small molecule	15 ug	Inhaled
Comparator	Salmeterol	Other / unclassified	12 ug	Inhaled
Comparator	Salmeterol	Other / unclassified	24 ug	Inhaled

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Summary

Timeline

Drugs

Indications